Background: There has been no phase III study of comparing the efficacy of first-and second-generation 5-HT 3 receptor antagonists in the triplet regimen with dexamethasone and aprepitant for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy (HEC).
introduction Chemotherapy-induced nausea and vomiting (CINV) is a nonhematologic toxicity of chemotherapy that severely impairs the quality of life of patients and reduces their treatment compliance. Cisplatin-based highly emetogenic chemotherapy (HEC) regimens, which are key treatments for some of malignant tumors, were conventionally administered after an antiemetic premedication with dexamethasone plus a 5-hydroxytryptamine 3 receptor antagonist (5-HT 3 RA) such as ondansetron or granisetron [1, 2] . As these doublet antiemetic therapies, however, sometimes failed to control CINV following HEC, there was an absolute need for more effective agents that would enhance emetic control.
Aprepitant, a neurokinin-1 (NK-1) receptor antagonist, and palonosetron, a second-generation 5-HT 3 RA, are two recently introduced antiemetic agents expected to improve control of CINV. Randomized controlled studies have shown that the addition of aprepitant to dexamethasone and a 5-HT 3 RA can achieve better CINV control when compared with the doublet antiemetic therapy [3, 4] . Current antiemesis guidelines from multiple organizations [American Society of Clinical Oncology (ASCO), Multinational Association of Supportive Care in Cancer/ European Society for Medical Oncology (MASCC/ESMO), and National Comprehensive Cancer Network (NCCN)] recommend aprepitant-containing triplet regimens as the standard antiemetic prophylaxis for patients receiving HEC [5] [6] [7] . Palonosetron has several advantageous features over first-generation 5-HT 3 RA, such as a longer plasma elimination half-life and a higher affinity for the 5-HT 3 receptor [8] . In patients receiving moderately emetogenic chemotherapy (MEC), better CINV control was obtained with palonosetron than with a first-generation 5-HT 3 RA [9] , which supports current guideline recommendations for palonosetron use as a part of antiemetic premedication for MEC.
In this paper, we will report the results of randomized phase III study to evaluate the efficacy of palonosetron versus granisetron in the standard triplet antiemetic therapy for cisplatinbased HEC.
patients and methods patients
Patients with cisplatin-naïve solid tumor were eligible if they were to receive a cisplatin (≥50 mg/m 2 )-based HEC regimen in hospital admission. Patients with previous cisplatin use could be enrolled if they received it >3 months before enrolment. Other inclusion criteria included age ≥20 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, adequate organ functions within 8 days before enrolment (aspartate transaminase <100 IU/l, alanine transaminase <100 IU/l, total bilirubin <2.0 mg/dl, creatinine clearance ≥60 ml/min), and written informed consent by the patient before enrolment. Patients with any of the following conditions were not included in the study: (i) inability to stay at the study hospital during the period from the cisplatin dose on day 1 until 120 h post-dose; (ii) the current use of any drugs with antiemetic activity (e.g. 5-HT 3 RA, corticosteroid, dopamine receptor antagonist, minor tranquilizer, antihistamine, and benzodiazepine); (iii) gastrointestinal obstruction; (iv) ascites or pleural effusion; (v) symptomatic brain metastasis; and (vi) current radiotherapy directed toward the abdomen/pelvis. In addition, patients with any uncontrolled complications and pregnant women were also excluded.
The study was conducted according to the Declaration of Helsinki and approved from the institutional review boards at each site. Before commencement, this study was registered at UMIN Clinical Trials Registry as UMIN000004863.
protocol treatments
An HEC regimen composed of cisplatin (≥50 mg/m 2 ) with or without one or more currently available anticancer drugs could be used. The prophylactic antiemetic regimen to be used during the first cycle of HEC consisted of intravenous palonosetron (0.75 mg) or granisetron (1 mg) on day 1 in addition to oral aprepitant (125 mg on day 1 and 80 mg/day on days 2-3) and intravenous dexamethasone phosphate sodium [dexamethasone; 12 mg (equivalent to 9.9 mg of dexamethasone) on day 1 and 8 mg/day (equivalent to 6.6 mg of dexamethasone) on days 2-4]. On day 1, patients received palonosetron or granisetron together with dexamethasone as an infusion over <15 min at least 30 min before the cisplatin dose. Patients took aprepitant at least 60 min before the cisplatin dose on day 1 and before breakfast on days 2-3.
No other drugs with antiemetic activity were allowed during the study. After randomization, patients who received any such drug within 24 h before administration of study treatment were withdrawn from the study. Patients also discontinued the study if they developed any emetic episode (vomiting or retching) or Common Terminology Criteria for Adverse Events (CTCAE version 4) Grade 2 or higher nausea within 24 h before the start of the treatment.
end points
The primary end point of this study was overall complete response (CR) rate, which was defined as the proportion of patients with no emetic episode and no use of rescue antiemetic medication over the 120 h period after the start of cisplatin treatment. The secondary end points were: (i) CR rates in the acute (0-24 h) and delayed (24-120 h) periods, (ii) complete control (CC) rates, defined as the proportions of patients with no emetic episode, no use of rescue medication, and no more than mild nausea. Severity of nausea was measured by the 4-point Likert scale (0, no nausea; 1, mild; 2, moderate; 3, severe [10] ) and (iii) total control (TC) rates, defined as the proportions of patients with no emetic episode, no use of rescue medication, and no nausea. Other secondary end points included time to treatment failure (TTF; time to first emetic episode or use of rescue medication) and treatment-related adverse events.
Nausea was assessed by patients themselves with the Likert scale and the results were recorded in daily diaries. A rescue medication was conducted whenever investigators determine it was necessary for CINV or patients desired it. Usual antiemetic therapy such as metoclopramide, domperidone, and dexamethasone can be administered, but addition of granisetron or palonosetron was prohibited.
hospitalization and study pharmacists
All patients were hospitalized during the 5-day period of observation. This minimized the effect of external factors on the onset of nausea and vomiting, such as carsickness or smell, for patients receiving chemotherapy. Also, our study designated study pharmacists at each center who were blinded (masked) to treatment allocation and who evaluated efficacy end points for each patient every day based on diary data and interview. The assignment of study pharmacists together with hospitalization were for the rigorous assessment of nausea and vomiting and rescue medication use.
randomization Eligible patients were randomized to receive either palonosetron (Arm P) or granisetron (Arm G) as a part of a prophylactic antiemetic regimen. Randomization was done centrally using the minimization method with stratification with respect to center, age (<60 versus ≥60 years), gender, and cisplatin dose (<70 versus ≥70 mg/m 2 ).
At each center, one pharmacist was pre-designated who was notified of treatment label (i.e. non-blinded) and responsible for preparing dose solutions of the assigned study drug (palonosetron or granisetron) admixed with
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statistical analyses
This trial was initially designed with a sample size of 640 to detect a 10% increase in overall CR rate with 80% statistical power, assuming that an overall CR rate of 70% in the control arm [11] with one-sided type 1 error rate of 0.025 level. In October 2011, the trial Steering Committee held a regular meeting under data masking and they discussed the increase in statistical power to 90% from 80% based on the observation of much faster enrollment speed than expected. The revised sample size was 840 patients (420 per arm). This proposal was approved by the Independent Data Monitoring Committee (IDMC) in November 2011 and the protocol revision for this was conducted in December 2011.
The exact Cochran-Mantel-Haenszel (CMH) test was used to compare CR, CC, and TC rates between the two treatment arms with strata of age, gender, and cisplatin dose. The Breslow-Day test was used to assess homogeneity across the strata. TTF curves were estimated by the Kaplan-Meier method and hazard ratio between the two arms was estimated by stratified Cox proportional hazards model. Efficacy analyses were carried out on the full analysis set (FAS) which consisted of all randomized patients with confirmed eligibility and with receiving both cisplatin (≥50 mg/m 2 ) and the protocol antiemetic treatment. All tests were reported as two-sided. All statistical analyses were carried out with SAS Version 9.2.
results patient characteristics
A total of 842 patients were enrolled at 20 Japanese centers between July 2011 and June 2012 and randomly assigned to either Arm P or G. The disposition of patients is shown in Figure 1 . Eleven patients (4 in Arm P and 7 in Arm G) were withdrawn from analyses. Three additional patients were withdrawn according to discontinuation criteria because they developed emesis (two in Arm P) or used a drug with antiemetic activity (one in Arm G) within 24 h before the start of study treatment. These 14 patients were excluded from analyses, leaving 828 patients (415 in Arm P and 413 in Arm G) evaluable for safety (safety population). One patient in Arm P had no efficacy data due to a serious adverse event soon after the antiemetic treatment. Thus, the FAS comprised 827 patients (414 in Arm P and 413 in Arm G).
Patient characteristics in the FAS are summarized in Table 1 . Overall, baseline characteristics were well balanced between the two treatment arms. The detailed summary of chemotherapy regimens is provided in supplementary Table S1 , available at Annals of Oncology online.
efficacy
All efficacy analyses were carried out on the FAS which was defined previously. The results for primary end point are shown in 
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Arm P had a longer TTF [supplementary Figure S1 , available at Annals of Oncology online; hazard ratio = 0.81 (95% CI 0.65-1.01)] when compared with Arm G but with a stratified log-rank P-value of 0.063. Of a total of 311 treatment failures, 101 were emetic episodes and 210 were the needs for rescue therapy. The results for CC and TC are summarized in Table 3 . It can be observed that the acute CC and TC rates were equivalent for the two arms while, in terms of the delayed CC and TC rates, Arm P is significantly superior to Arm G. Figure 2 shows the results of subgroup analysis for the primary end point. The results tended to favor palonosetron over granisetron in all subgroups examined. safety Treatment-related adverse events in ≥2% of patients in either treatment arm are listed in supplementary Table S2 , available at Annals of Oncology online. Two grade 4 adverse events were observed in Arm G; one patient developed gastric perforation and one acute kidney dysfunction. These were judged to be unrelated to the study drug.
discussion
This was the first phase III study designed to elucidate the relative efficacy of first-and second-generation 5-HT 3 RAs in the triplet antiemetic regimen with aprepitant and dexamethasone. Current antiemesis guidelines recommend several first-generation 5-HT 3 RAs as prophylaxis for CINV, including granisetron, ondansetron, and dorasetron. Granisetron was chosen as the comparator in this study because of its common use than ondansetron in Japan and its equivalent efficacy to ondansetron shown by a meta-analysis of randomized, controlled studies [12] . In this study, palonosetron was administered intravenously at the dose of 0.75 mg. This dose is the same as used in PROTECT study [13] , a randomized study of palonosetron versus granisetron in the doublet antiemetic regimen with dexamethasone, but is different from that recommended in international antiemesis guidelines (0.25 mg). The results of two randomized phase II studies [14, 15] were used for determining the approved dose of palonosetron in Japan to be 0.75 mg and a meta-analysis of randomized studies comparing 0.75 versus 0.25 mg of palonosetron demonstrated similar efficacy for the two doses [16] . These consisted of a rationale for choosing 0.75 mg of palonosetron in this study. Although the primary end point was not met in this study (P = 0.0539), palonosetron showed its efficacy over granisetron in terms of controlling CINV. At the acute phase, CR, CC, and TC rates are the very same for Arm P and Arm G, while, at the delayed phase, the difference between the two arms are 8.1% for CR rate, 9.3% for CC rate, and 7.2% for TC rate (Tables 2 and  3) . MASCC/ESMO guideline [6] suggests a 10% improvement in end points could result in a change of guidelines for CINV. Since our result is on the near achievement of this goal, particularly in the delayed phase, this may reasonably justify the use of palonosetron in a three drug program for HEC.
This study evaluated the administration of palonosetron in the first cycle of chemotherapy only. No information in subsequent cycles was obtained, but there has been a clinical trial that confirmed the maintenance of efficacy of palonosetron combined with dexamethasone in patients receiving repeated cycles of HEC [17] .
One aspect we need to consider in choosing a 5-HT 3 RA is the budget impact of adopting palonosetron; its cost is more expensive than other 5-HT 3 RA such as granisetron and ondansetron. For example, the cost of 0.75 mg palonosetron is 135 dollars, whereas that of 1 mg granisetron (generic) is 10 dollars in Japan. We are currently undertaking the economic analysis of TRIPLE study to analyze the cost-effectiveness of palonosetron.
In conclusion, the present study did not show the superiority of palonosetron when compared with granisetron in the primary end point and should be concluded as a negative result. We, however, observed that palonosetron achieved the same efficacy as granisetron at the acute period as well as significantly higher CR, CC, and TC rates than granisetron at the delayed period, suggesting the need to discuss the clinical implications of these results in choosing 5-HT 3 RA for controlling HEC-related CINV.
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